The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful clinical testing.
The patch contains a formulation of asenapine which is used to manage symptoms of schizophrenia and bipolar disorder and is the first of its kind. Schizophrenia now affects around 20 million people worldwide. It’s a debilitating mental disorder that can cause hallucinations, delusions and trouble concentrating.

Richmond Pharmacology are proud to have been involved in the patch’s development since 2014 when we investigated its effectiveness in patients during early-phase testing. Patients reported feeling happier and noted fewer side effects compared to tablets and injections.


For schizophrenia patients who, until recently, only had limited therapeutic options, the patch formulation offers several advantages. It delivers asenapine more gradually into the blood stream over a 24-hour period. Gradual absorption has been shown to reduce the side effects of medications. That’s because a smaller amount of a therapeutic compound is delivered over a longer period of time. At the same time, patients experience fewer gastrointestinal complaints because the gut is bypassed.

The patch formulation is also a more comfortable treatment option compared to injections or tablets because patients don’t need to remember to swallow their pills at certain times or have to travel long distances to receive an injection.

The patch passed phase III testing back in 2018 and is now officially available under the brand name Secuado.

Latest news

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

September 19, 2022
We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management
Read more

How telemonitoring can revolutionise the way we treat patients – Tom York

November 17, 2022
Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments.
Read more

Events

JPW2022 (Japan Basic and Clinical Pharmacology Week 2022)

30 November – 3 December 2022
This event will be the 96th Annual Meeting of the Japanese Pharmacological Society and the 43rd Annual Meeting of the Japanese Society of Clinical Pharmacology. 
View event